BRPI1002094A2 - Utilização de pelo menos uma forma peptidica solúvel, e processos de triagem de ativos anti-idade e de caracterização da eficácia de um tratamento - Google Patents

Utilização de pelo menos uma forma peptidica solúvel, e processos de triagem de ativos anti-idade e de caracterização da eficácia de um tratamento Download PDF

Info

Publication number
BRPI1002094A2
BRPI1002094A2 BRPI1002094-2A BRPI1002094A BRPI1002094A2 BR PI1002094 A2 BRPI1002094 A2 BR PI1002094A2 BR PI1002094 A BRPI1002094 A BR PI1002094A BR PI1002094 A2 BRPI1002094 A2 BR PI1002094A2
Authority
BR
Brazil
Prior art keywords
assets
characterizing
age
treatment
effectiveness
Prior art date
Application number
BRPI1002094-2A
Other languages
English (en)
Inventor
Donovan Mark
Simonetti Lucie
Bernard Dominique
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Publication of BRPI1002094A2 publication Critical patent/BRPI1002094A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

UTILIZAÇçO DE PELO MENOS UMA FORMA PEPTIDICA SOLéVEL, E PROCESSOS DE TRIAGEM DE ATIVOS ANTI-IDADE E DE CARACTERIZAÇçO DA EFICÁCIA DE UM TRATAMENTO. A invenção refere-se à utilização de forma(s) peptídica(s) solúvel(s), complexada(s) ou não, da desmogleina I, a título de marcador para a avaliação da eficácia de ativos e/ou de tratamentos, notadamente anti-idade, em relação a uma epiderme.
BRPI1002094-2A 2009-01-13 2010-01-12 Utilização de pelo menos uma forma peptidica solúvel, e processos de triagem de ativos anti-idade e de caracterização da eficácia de um tratamento BRPI1002094A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0950159A FR2940976B1 (fr) 2009-01-13 2009-01-13 Utilisation a des fins de criblage d'actifs anti-ages de formes solubles de la proteine de type desmogleine i
US20207809P 2009-01-27 2009-01-27

Publications (1)

Publication Number Publication Date
BRPI1002094A2 true BRPI1002094A2 (pt) 2012-03-06

Family

ID=41040658

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1002094-2A BRPI1002094A2 (pt) 2009-01-13 2010-01-12 Utilização de pelo menos uma forma peptidica solúvel, e processos de triagem de ativos anti-idade e de caracterização da eficácia de um tratamento

Country Status (7)

Country Link
US (1) US9316653B2 (pt)
EP (1) EP2209006B1 (pt)
JP (2) JP5820565B2 (pt)
KR (1) KR101431088B1 (pt)
BR (1) BRPI1002094A2 (pt)
ES (1) ES2564186T3 (pt)
FR (1) FR2940976B1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940977B1 (fr) 2009-01-13 2016-11-18 Oreal Utilisation de formes complexes de la proteine de type calmodulin-like skin protein clsp
CN102465182A (zh) * 2010-10-29 2012-05-23 株式会社爱茉莉太平洋 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法
US9279750B2 (en) 2013-03-15 2016-03-08 Iris International, Inc. Method and composition for staining and sample processing
FR3061305B1 (fr) * 2016-12-23 2021-02-12 Oreal Methode de diagnostic des qualites esthetiques de la peau
CN111982974B (zh) * 2020-08-29 2023-06-02 西北民族大学 一种利用气味指纹图谱无创评价驴乳清蛋白肽抗衰老性能的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152599A (en) * 1874-06-30 Improvement in organ-couplers
FR2667778B1 (fr) 1990-10-16 1995-05-12 Oreal Cellule permettant de collecter sur la peau, par circulation de liquide, au moins un compose a doser.
JP4197194B2 (ja) * 1997-10-08 2008-12-17 花王株式会社 細胞間接着抑制用経口投与剤
EP1075835A1 (en) 1999-08-09 2001-02-14 Shiseido Company Limited Use of aminodiol derivatives in skin cosmeics
JP2002012512A (ja) * 1999-08-09 2002-01-15 Shiseido Co Ltd 外用組成物
JP2001288113A (ja) * 2000-04-05 2001-10-16 Lion Corp 皮膚外用剤組成物
EP1356298B1 (en) * 2000-11-30 2011-05-18 Crawford Healthcare Holdings Limited Diagnosis of disease
DE10100121A1 (de) * 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
US20030161853A1 (en) * 2002-01-17 2003-08-28 L'oreal Methylglycinediacetic acid and deribatives thereof useful as exfoliating agents
JP2006006143A (ja) * 2004-06-23 2006-01-12 Hiroshima Univ 伝染性膿痂疹の診断方法および診断キット、ならびにこれらに用いるポリペプチドおよび抗体
JP2006008570A (ja) * 2004-06-24 2006-01-12 Club Cosmetics Co Ltd 表皮剥離毒素阻害剤及びこれを用いた皮膚外用剤
JP4805794B2 (ja) * 2005-12-28 2011-11-02 株式会社コーセー 角層蛋白質の検出方法並びにこれを利用する表皮ターンオーバーの評価方法及び肌状態評価方法
JP4281781B2 (ja) * 2006-10-26 2009-06-17 トヨタ自動車株式会社 燃料電池用セパレータ吸引装置
FR2925312B1 (fr) * 2007-12-19 2016-12-02 Oreal Utilisation cosmetique de proteines de type desmogleine i

Also Published As

Publication number Publication date
EP2209006B1 (fr) 2015-12-16
CN101980022A (zh) 2011-02-23
KR101431088B1 (ko) 2014-10-07
KR20100083741A (ko) 2010-07-22
JP6284897B2 (ja) 2018-02-28
JP2015158500A (ja) 2015-09-03
US20100216165A1 (en) 2010-08-26
US9316653B2 (en) 2016-04-19
FR2940976A1 (fr) 2010-07-16
FR2940976B1 (fr) 2017-11-03
JP5820565B2 (ja) 2015-11-24
JP2010175538A (ja) 2010-08-12
EP2209006A1 (fr) 2010-07-21
ES2564186T3 (es) 2016-03-18

Similar Documents

Publication Publication Date Title
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
CR20120202A (es) Métodos y composiciones para tratar cáncer
BR112015020466A2 (pt) inibidores de cdc7
BRPI0922301A2 (pt) combinações de inibidor de hsp90
BRPI1000030A2 (pt) métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
CL2012002404A1 (es) Compuestos derivados de urea, inhibidores de inmunoproteasomas; composición farmacéutica que comprende al compuesto; utiles en enfermedades inmunes, cancer, inflamacion, infecciones, enfermedad neurodegenerativa, entre otras.
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
BR112012029897A2 (pt) método para reduzir a quantidade de uma serina protease ou um zimogênio de serina protease em uma composição, método para preparar uma composição, composição de proteína derivada de plasma, e, método para tratamento de uma doença
WO2012092336A3 (en) Molecular profiling for cancer
EP3722810A3 (en) Molecular profiling of tumors
MX2011006685A (es) Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
NI201200175A (es) Métodos de tratamiento de cáncer de vejiga
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
AR065984A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. composiciones farmaceuticas.
BRPI0906167A2 (pt) uso de inibidor de serina protease no tratamento de doenças de pele.
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07A Technical examination (opinion): publication of technical examination (opinion)
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B09B Decision: refusal
B09B Decision: refusal